CA2352178A1 - Phospholipid compositions - Google Patents
Phospholipid compositions Download PDFInfo
- Publication number
- CA2352178A1 CA2352178A1 CA002352178A CA2352178A CA2352178A1 CA 2352178 A1 CA2352178 A1 CA 2352178A1 CA 002352178 A CA002352178 A CA 002352178A CA 2352178 A CA2352178 A CA 2352178A CA 2352178 A1 CA2352178 A1 CA 2352178A1
- Authority
- CA
- Canada
- Prior art keywords
- lipid
- composition
- polymer
- active compound
- solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9827006.9 | 1998-12-08 | ||
GB9827006A GB2344520A (en) | 1998-12-08 | 1998-12-08 | Pharmaceutical carriers comprising lipids and polymers |
GB9925365.0 | 1999-10-27 | ||
GBGB9925365.0A GB9925365D0 (en) | 1999-10-27 | 1999-10-27 | Phospholipid compositions |
PCT/GB1999/004070 WO2000033817A1 (en) | 1998-12-08 | 1999-12-08 | Phospholipid compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2352178A1 true CA2352178A1 (en) | 2000-06-15 |
Family
ID=26314804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002352178A Abandoned CA2352178A1 (en) | 1998-12-08 | 1999-12-08 | Phospholipid compositions |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1137402A1 (de) |
JP (1) | JP2002532389A (de) |
AU (1) | AU1787800A (de) |
CA (1) | CA2352178A1 (de) |
WO (1) | WO2000033817A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021055820A1 (en) | 2019-09-20 | 2021-03-25 | Novartis Ag | 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation |
WO2022195545A1 (en) | 2021-03-18 | 2022-09-22 | Novartis Ag | Novel pharmaceutical formulations |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1498420B1 (de) | 2002-03-29 | 2017-02-01 | Nof Corporation | Phospholipidderivat |
US7531604B2 (en) | 2002-09-30 | 2009-05-12 | Nof Corporation | Phospholipid derivative |
JP4403303B2 (ja) | 2003-01-06 | 2010-01-27 | 日油株式会社 | リン脂質誘導体及びその製造方法 |
GB0305941D0 (en) * | 2003-03-14 | 2003-04-23 | Camurus Ab | Composition |
WO2004083219A1 (ja) | 2003-03-20 | 2004-09-30 | Nof Corporation | リン脂質誘導体 |
CN100553680C (zh) | 2004-02-17 | 2009-10-28 | 卫材R&D管理有限公司 | 软胶囊剂 |
WO2006103657A2 (en) * | 2005-03-31 | 2006-10-05 | Dexcel Pharma Technologies Ltd. | A solid composition for intra-oral delivery of insulin |
EP1952803A1 (de) | 2007-01-23 | 2008-08-06 | KTB-Tumorforschungs GmbH | Feste pharmazeutische Darreichungsform mit hydrierten Phospholipiden |
JP5196833B2 (ja) * | 2007-04-07 | 2013-05-15 | ヤヱガキ醗酵技研株式会社 | 機能性食品素材とその製造方法 |
WO2009071295A1 (en) * | 2007-12-05 | 2009-06-11 | Dsm Ip Assets B.V. | Pulverous formulation of a fat-soluble active ingredient |
US8603568B2 (en) | 2010-01-15 | 2013-12-10 | Kemin Industries, Inc. | Hydrolyzed lecithin product to improve digestibility |
WO2012070031A1 (en) * | 2010-11-26 | 2012-05-31 | University Of The Witwatersrand, Johannesburg | Polymeric matrix of polymer-lipid nanoparticles as a pharmaceutical dosage form |
US10722458B2 (en) | 2011-12-02 | 2020-07-28 | Pegasus Laboratories, Inc. | Amphipathic lipid-based sustained release compositions |
GB201415381D0 (en) * | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
EP3212169B1 (de) * | 2014-10-31 | 2021-01-13 | Bend Research, Inc. | Verfahren zur herstellung von in einer matrix dispergierten aktiven domänen |
CN108366978B (zh) * | 2015-10-09 | 2021-06-01 | 三荣源有限公司 | 含有多酚的固体组合物 |
CN114831128A (zh) * | 2022-04-06 | 2022-08-02 | 安徽华辰检测技术研究院有限公司 | 一种含有苯醚甲环唑和嘧菌酯的农药制剂 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5002940A (en) * | 1984-11-06 | 1991-03-26 | Ciba-Geigy Corporation | Solid drug formulations and stable suspensions |
CN1065415C (zh) * | 1993-02-05 | 2001-05-09 | 花王株式会社 | 蛋白质和类脂复合体用于改善味觉的用途 |
JPH06245719A (ja) * | 1993-02-19 | 1994-09-06 | Nippon Oil & Fats Co Ltd | 粉末乳化剤および製造方法 |
JPH07291854A (ja) * | 1994-04-26 | 1995-11-07 | Tanabe Seiyaku Co Ltd | 溶解性の改善された医薬品製剤 |
DE19531277A1 (de) * | 1995-08-25 | 1997-02-27 | Basf Ag | Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren |
GB2326337A (en) * | 1997-06-20 | 1998-12-23 | Phares Pharma Holland | Homogeneous lipid compositions for drug delivery |
-
1999
- 1999-12-08 JP JP2000586310A patent/JP2002532389A/ja active Pending
- 1999-12-08 WO PCT/GB1999/004070 patent/WO2000033817A1/en not_active Application Discontinuation
- 1999-12-08 CA CA002352178A patent/CA2352178A1/en not_active Abandoned
- 1999-12-08 EP EP99961183A patent/EP1137402A1/de not_active Ceased
- 1999-12-08 AU AU17878/00A patent/AU1787800A/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021055820A1 (en) | 2019-09-20 | 2021-03-25 | Novartis Ag | 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation |
WO2022195545A1 (en) | 2021-03-18 | 2022-09-22 | Novartis Ag | Novel pharmaceutical formulations |
Also Published As
Publication number | Publication date |
---|---|
WO2000033817A1 (en) | 2000-06-15 |
JP2002532389A (ja) | 2002-10-02 |
EP1137402A1 (de) | 2001-10-04 |
AU1787800A (en) | 2000-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2352178A1 (en) | Phospholipid compositions | |
Yuksel et al. | In situ niosome forming maltodextrin proniosomes of candesartan cilexetil: in vitro and in vivo evaluations | |
JP4969104B2 (ja) | 多孔質セルロース凝集体及びその成型体組成物 | |
Huang et al. | A novel plug-controlled colon-specific pulsatile capsule with tablet of curcumin-loaded SMEDDS | |
KR101824831B1 (ko) | 신규 멜록시캄 제제 | |
CN102256597A (zh) | 制备含有不溶性药物的纳米颗粒的粉末的方法、由此制备的粉末以及含有该粉末的药物组合物 | |
SG177281A1 (en) | Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them | |
JP2020531424A (ja) | メロキシカムを含有する注射用医薬組成物、およびその製造方法 | |
CN102014910A (zh) | 在无食物条件下施用齐拉西酮的方法、剂型和试剂盒 | |
US6376481B2 (en) | Sterol esters in tableted solid dosage forms | |
AU2010261512A1 (en) | Nanoparticulate Candesartan Cilexetil compositions, process for the preparation thereof and pharmaceutical compositions containing them | |
AU2010261511A1 (en) | Nanoparticulate Olmesartan Medoxomil compositions, process for the preparation thereof and pharmaceutical compositions containing them | |
CN102892411A (zh) | 含有合成的低聚糖的药物口服剂型 | |
CN104188926A (zh) | 化学物质的胶束纳米颗粒 | |
AU2008300030A1 (en) | Pharmaceutical compositions for oral use for treating patients affected by obesity | |
DE60309356T2 (de) | Zusammensetzung, durch zusammen vermahlen eines wirkstoffes mit einem n-vinyl-2-pyrrolidon/vinylacetatkopolymers erhältlich | |
CN110381945A (zh) | 口服给予的镓(iii)配合物的组合物 | |
CN103040764A (zh) | 一种盐酸平阳霉素脂质体注射剂 | |
CN103142518B (zh) | 一种阿格列汀脂质体固体制剂及其制备方法和应用 | |
US20050215455A1 (en) | Surfactants in powdered form that can be used in tablets or gelatin capsules; preparation process and compositions containing them | |
US20230165804A1 (en) | Solid lipid nanoparticle for intracellular release of active substances and method for production the same | |
AU2004324858A1 (en) | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby | |
US20070292503A1 (en) | Oral pharmaceutical composition of poorly water-soluble active substance | |
KHAZIM et al. | Formulation of probiotics loaded granules of 5-Amino salicylic acid for colon targeting drug delivery system | |
Jain et al. | Dual Component Tablets for the Treatment of Gastroesophageal Reflux Disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |